- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00560612
Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Durham VAMC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Veterans 18-55 years of age
- Diagnosis of subthreshold PTSD (at least one symptom in PTSD symptom clusters B, C, and D by structured interview; with or without functional impairment exposure to war zone stressors)
- Written informed consent; and
- A negative serum pregnancy test for women of childbearing potential.
Exclusion Criteria:
- Lifetime history of DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, or cognitive disorder due to a general medical condition
- History of substance dependence within the last 3 months
- Significant suicide risk or serious suicide attempt within the last year
- Clinically significant medical condition or laboratory or EKG abnormality
- Women of childbearing potential who are unwilling to practice an acceptable method of contraception
- Subjects needing concurrent use of psychiatric medications
- History of hypersensitivity to paroxetine
- HADS depression subscale score > 12
- Failure to respond to an adequate trial of paroxetine (20 mg/day x 8 wks).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo: same as paroxetine (active comparator)
|
Active Comparator: Paroxetine
Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
|
Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Clinician Administered PTSD Scale (CAPS) Scores
Time Frame: Change in Scores (12 weeks-Baseline)
|
Mean change scores in posttraumatic stress disorder symptoms. Raw scores may range from 0 (no symptoms) to 136 (severe symptoms; score of 136 is based on the first 17 CAPS items administered). A reduced CAPS score indicates a reduction in (improvement) PTSD symptoms, while an increase in CAPS score indicates an increase (worsening) in PTSD symptoms. The outcome measure is the change in scores before and after treatment. That is, the baseline and at 12 weeks difference scores. |
Change in Scores (12 weeks-Baseline)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Short PTSD Rating Interview Scores
Time Frame: Change in Scores (12 weeks-Baseline)
|
The SPRINT contains 8 questions which are rated on a 0-4 scale (0=not at all; 4=very much).
The total score is computed from summing questions #1-8 (range=0-32).
The higher the total score, the worse the symptoms.
The outcome measure is the change in scores before and after treatment.
That is, the baseline and Visit 6 difference scores.
|
Change in Scores (12 weeks-Baseline)
|
Change in Connor Davidson Resilience Scale Scores
Time Frame: Change in Scores (12 Weeks-Baseline)
|
This scale measures resilience.
Range of scores (0-100).
A score of 0 is suggestive of no resilience, a score of 100 is suggestive of high level of resilience.
The outcome measure is the change in scores before and after treatment.
That is, the baseline and Visit 6 difference scores.
|
Change in Scores (12 Weeks-Baseline)
|
Change in Hospital Anxiety and Depression Scale Scores
Time Frame: Change in Scores (12 Weeks-Baseline)
|
The total HADS score is presented, which is regarded as a global measure of psychological distress.
The total score ranges from 0-42.
Each individual question is rated on a 4 point scale (0=absent to 3 =extreme presence).
The higher the score, the greater level of psychological distress.
The outcome measure is the change in scores before and after treatment.
That is, the baseline and Visit 6 difference scores.
|
Change in Scores (12 Weeks-Baseline)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christine E Marx, MD, MA, Durham VAMC
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Trauma and Stressor Related Disorders
- Stress Disorders, Traumatic
- Stress Disorders, Post-Traumatic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Paroxetine
Other Study ID Numbers
- VA IRB# 00993
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stress Disorders, Post-Traumatic
-
University of California, Los AngelesDefense Advanced Research Projects Agency; Defense Group, Inc.CompletedPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder, ChronicUnited States
-
Weill Medical College of Cornell UniversityCompletedPost-traumatic Stress Disorder | Complex Post-Traumatic Stress DisorderUnited States
-
Oregon Health and Science UniversityNational Center for Complementary and Integrative Health (NCCIH); Oregon Clinical...CompletedPost-Traumatic Stress DisordersUnited States
-
US Department of Veterans AffairsEmory UniversityWithdrawnPost-Traumatic Stress Disorders
-
University of KonstanzGerman Research Foundation; NGO vivo e.V.; GTZ-German Technical Cooperation,... and other collaboratorsCompletedPost-Traumatic Stress DisordersSri Lanka
-
University Hospital, ToulouseCompletedPost-traumatic StressFrance
-
University of California, Los AngelesRecruitingPost-traumatic Stress Disorder | Post-Traumatic Stress Disorder in ChildrenUnited States
-
University of UtahEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedPost-Traumatic Stress Disorder in Children | Post-Traumatic Stress Disorder in AdolescenceUnited States
-
University Hospital, LilleNot yet recruiting
-
Steinn SteingrimssonRecruiting
Clinical Trials on Paroxetine
-
GlaxoSmithKlineCompletedDepressive DisorderKorea, Republic of, Japan
-
GlaxoSmithKlineTerminatedDepressive DisorderJapan
-
GlaxoSmithKlineCompletedDepressive DisorderJapan
-
GlaxoSmithKlineCompletedDepressive Disorder, Major | Major Depressive Disorder (MDD)China
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
Oizumi HospitalUnknown
-
University of GöttingenGlaxoSmithKlineCompleted
-
Noven TherapeuticsCompleted